Therapeutic ultrasound for brain disorders


At CarThera, we have by-passed the problem of the skull bone by taking advantage of the necessary clinical step of tumor biopsy before any treatment. No clinician worldwide can envision beginning a chemotherapy or radiotherapy treatment without a previous histological diagnosis. We have designed and developed a probe that is able to emit high intensity ultrasound that can be inserted within the tumor as a biopsy needle under local anesthesia.  The probe performs not only the necessary biopsy but also the ultrasound treatment of the tumor in the same procedure under real-time MRI control.



Ultrasound emitted at a lower intensity is also able to interact with the biological tissue without destroying it. Using low-intensity pulsed ultrasound, it is possible to temporarily make the blood vessels more porous to drugs. In the brain, the vessels are particularly tight (Blood-Brain Barrier or BBB), preventing the penetration of chemotherapy in the brain and significantly reducing its effectiveness.

At CarThera®, we have developed an implantable medical device containing a low intensity ultrasound transducer, the SonoCloud®, which is able to temporarily open the blood-brain barrier. At each chemotherapy session, the BBB can be opened in order to optimize the penetration of the chemotherapy in the brain while reducing the side effects in the rest of the body.

  • unnamed-2

  • News CarThera

    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.

    A world first published in Science Translational Medicine

    SonoCloud® uses ultrasound to achieve permeability of blood vessels in human brain, allowing increased penetration of therapeutic molecules

    Scientific paper published on June 15th 2016 in Science Translational Medicine supports concept of intracranial ultrasound implant developed by CarThera
    Research teams from AP-HP hospitals, UPMC University, INSERM laboratories and the ICM incubator performed this breakthrough on brain tumors, paving the way for broader applications in neurological disorders

    The Biovision 2016 Investor Conference selection committee special award went to CarThera!

    The Investor Conference of Biovision is a unique opportunity for selected startups (28 over 120 candidates) to pitch in front of a jury of 15 of the major European VC.

    Biovision, The World Life Sciences Forum, brings together international decision makers from the academic, private, policy-making and civil society sectors. It took place 13–14 April 2016 in Lyon, France.